PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Provention Bio wins approval for first-in-class diabetes drug

NJ-based Provention Bio has announced that the U.S. FDA has approved its intravenous diabetes drug — the first and only immunomodulatory treatment to delay the onset of stage 3 type 1 diabetes in adults and kids with stage 2 type 1 diabetes.

The new drug, branded as Tzield, was evaluated in a  placebo-controlled trial with 76 patients with stage 2 type 1 diabetes. In the trial, patients randomly received Tzield or a placebo once daily. The trial results showed that over a median follow-up of 51 months, 45% of the 44 patients who received Tzield were later diagnosed with stage 3 type 1 diabetes, compared to 72% of the 32 patients who received a placebo.

Type 1 diabetes occurs when the immune system attacks and destroys the cells that make insulin. People with a type 1 diabetes diagnosis have increased glucose that requires insulin shots (or they have to wear an insulin pump) to survive and must check their blood sugar levels regularly.

“The drug’s potential to delay clinical diagnosis of type 1 diabetes may provide patients with months to years without the burdens of disease,” said John Sharretts, M.D., director of the Division of Diabetes, Lipid Disorders, and Obesity at the FDA’s CDER.

Tzield — which is administered by intravenous infusion once daily for 14 consecutive days — binds to certain immune system cells and delays progression to stage 3 type 1 diabetes. The drug may deactivate the immune cells that attack insulin-producing cells while increasing the proportion of cells that help moderate the immune response.

The drug has a long history. Back in 2007, Eli Lilly and MacroGenics partnered to develop and commercialize teplizumab. Then, in 2010, teplizumab failed a pivotal late-stage diabetes study undertaken by Eli Lilly and the drugmaker handed the rights back to MacroGenics. In 2018, Provention in-licensed the drug from MacroGenics and used it as their lead drug for a $56 million IPO filing.

For Provention, the approval is a hard-fought win. The drugmaker first filed its BLA for teplizumab back in January of 2021 but faced some roadblocks a few months later when the FDA uncovered “deficiencies” in the marketing application. More recently, in July, the agency extended the review period for the drug’s BLA by three months.

Last month, Provention announced a co-promotion agreement for the U.S. launch of Tzield with Sanofi.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026